Strutton David R, Walt John G. J. Glaucoma 2004,13:221-226.
Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France. Kenigsberg PA. Eur J Ophthalmol. 2007 Jul-Aug; 17(4):521-7. Erratum in: Eur J Ophthalmol. 2007 Nov-Dec; 17(6):1010.
European Glaucoma Society. Terminology and Guidelines for Glaucoma. Savona Italia:Dogma 2003.
AAO Guidelines for Glaucoma Treatment. San Francisco: American Academy of Ophthalmology, 2005.
Asociacion Mexicana de Glaucoma. Lineamientos y Recomendaciones para el manejo del Glaucoma. Mexico: Intersistemas SA de CV 2005.
The Preferred Practice Pattern for Primary Open Angle Glaucoma. San Francisco: American Academy of Ophthalmology 2005.
Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZiapreserved topical glaucoma medications on human ocular epithelial cells. Ammar DA, Noecker RJ, Kahook MY. Adv Ther. 2010 Nov; 27(11):837-45. Epub 2010 Oct 7.
Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. Aptel FCucherat MDenis P. J. Glaucoma 2008 Dec;17(8):667-73.
The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis. Webers CABeckers HJZeegers MPNuijts RMHendrikse FSchouten JS. Ophthalmology. 2010 Nov;117(11):2067-74.e1-6.
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
Jampel HD. Target Pressure in Glaucoma Therapy. J Glaucoma 1997:6:133-138.
Effectiveness of dorzolamide.timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study, Crichton AC, Harasymowycz P, Hutnik CM, Behki R, Boucher S, Ibrahim F, Rifkind AW, Solomon L, Liao C, Bastien NR, Sampalis JS.J Ocul Pharmacol Ther. 2010 Oct;26(5):503-11.
Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R; Combigan Study Group. J Ocul Pharmacol Ther. 2005 Aug;21(4):337-48.
Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma. Januleviciene I. Curr Med Res Opin. 2010 Nov;26(11):2575-8. Epub 2010 Sep 27.
Denis P, Lafuma A, Jeanbat V, Laurendeau C, Berdeaux G. Intraocular Pressure Control with Latanoprost/Timolol and Travoprost/Timolol Fixed Combination. A Retrospective, Multicentre, Cross-Sectional Study. Clin Drug Invest 2008; 28 (12).
Bimatoprost and bimatoprost/timolol fixed combination in patients with openangle glaucoma and ocular hypertension. Katsanos A, Dastiridou AI, Fanariotis M, Kotoula M, Tsironi EE.J Ocul Pharmacol Ther. 2011 Feb;27(1):67-71. Epub 2011 Jan 7.
Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, doublemasked, study of the safety and efficacy of Travoprost 0.004%/Timolol 0.5% ophthalmic solution compared to Travoprost 0.004% ophthalmic solution and Timolol 0.5% dosed concomitantly in subjects with open-angle glaucoma or ocular hypertension. J Glaucoma. In press.
El Estudio Colaborativo de Tratamiento de Glaucoma Inicial Lichter et al. Ophthalmology. 2001; Robin et al. AGS. 2003.
Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg.1995,26(3):234-236.
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
